Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:CALA NASDAQ:EGLT NASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01+84.9%$0.01$0.06▼$0.33N/AN/A34,287 shs5,100 shsCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.8211,015 shs94 shsEGLTEgalet$0.01$0.24$0.03▼$1.57N/AN/A853,425 shsN/ANTHINeonc Technologies$4.75-3.1%$5.44$3.20▼$25.00N/AN/A173,080 shs35,928 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition+276.92%+276.92%+7.34%-10.75%-79.10%CALACalithera Biosciences0.00%0.00%0.00%-98.00%-99.20%EGLTEgalet0.00%0.00%0.00%0.00%0.00%NTHINeonc Technologies0.00%-6.86%-18.52%+8.94%+474,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEGLTEgaletN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/AEGLTEgalet 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AEGLTEgaletN/AN/AN/AN/AN/AN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/AEGLTEgaletN/AN/A0.00∞N/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest EGLT, AEHAW, CALA, and NTHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AEGLTEgaletN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera BiosciencesN/AEGLTEgalet19.20%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera Biosciences6.60%EGLTEgalet2.40%NTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableEGLTEgaletN/AN/AN/AOptionableNTHINeonc Technologies8N/AN/AN/AEGLT, AEHAW, CALA, and NTHI HeadlinesRecent News About These CompaniesNeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of DirectorsJuly 30, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc.: NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finanznachrichten.deNeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finance.yahoo.comAI and biotech take on brain cancerJuly 30, 2025 | finance.yahoo.comNeOnc Technologies to Participate at the BTIG Virtual Biotechnology ConferenceJuly 28, 2025 | tmcnet.comNeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar InvestmentJuly 24, 2025 | finance.yahoo.comNeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on ...July 24, 2025 | bakersfield.comBCORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.July 23, 2025 | globenewswire.comNeOnc Technologies Secures Board Approval for $50 Million Strategic ...July 12, 2025 | seekingalpha.comNeOnc Technologies Holdings, Inc. Secures Board Approval for ... - NasdaqJuly 12, 2025 | nasdaq.comNeOnc Technologies Announces UAE Investment PartnershipJuly 11, 2025 | msn.comNeOnc Technologies Holdings Inc. (NTHI) Stock Price Today - WSJJuly 10, 2025 | wsj.comNeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar InvestmentJuly 10, 2025 | finance.yahoo.comNeOnc Technologies stock soars on planned $50M UAE investment dealJuly 10, 2025 | uk.investing.comNeOnc Technologies Holdings, Inc. Forms New UAE-Based Investment Platform NuroMENA for Clinical Trials in MENA Region - NasdaqJuly 10, 2025 | nasdaq.comNeOnc Technologies Holdings, Inc. Joins Russell Microcap® IndexJuly 10, 2025 | finance.yahoo.comNeOnc Technologies Stock Climbs on $50 Million UAE Investment FrameworkJuly 8, 2025 | msn.comNeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials PlatformJuly 8, 2025 | globenewswire.comNeOnc Technologies Holdings Insiders Lose Out As Stock Sinks To US$3.72June 26, 2025 | finance.yahoo.comNeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology ProgramsJune 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGLT, AEHAW, CALA, and NTHI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0098 +0.00 (+84.91%) As of 08/1/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Egalet NASDAQ:EGLTEgalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.Neonc Technologies NASDAQ:NTHI$4.75 -0.15 (-3.06%) As of 08/1/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
